RLG Relieved by FDA Decision to Heighten Sexual-Adverse-Event Warnings on Propecia and Proscar Labels
The Rottenstein Law Group is heartened by the FDA’s April 12, 2012, expansion of Propecia’s and Proscar’s warning labels to include a broader range of adverse sexual events.
“Propecia labels will now include warnings for libido disorders, ejaculation disorders, and orgasm disorders that continued for men even months after stopping the drug,” according to CBS News. “Proscar’s label will include a ‘decreased libido’ warning that continues after drug discontinuation. Both drugs’ labels will also include a new description of reported cases of male infertility and poor semen quality that improved after patients stopped taking the drug.”
By including these disclosures, the new labels will forewarn potential Propecia and Proscar patients about the full extent of those drugs’ potential negative side effects—news that the Rottenstein Law Group has long been publicizing.
